Published in Mol Cell Endocrinol on January 14, 2016
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int (2004) 2.47
Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci (2005) 2.31
Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci (2002) 2.00
Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci (2001) 1.91
Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature (1990) 1.91
Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A (2001) 1.88
The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch (2003) 1.75
Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A (2012) 1.51
Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr (2006) 1.50
The glutamate story. Br J Pharmacol (2006) 1.45
Glutamate signaling in peripheral tissues. Eur J Biochem (2004) 1.42
Glutamatergic dysfunction in OCD. Neuropsychopharmacology (2005) 1.36
Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr (2006) 1.25
Acute decrease in net glutamate uptake during energy deprivation. Proc Natl Acad Sci U S A (2000) 1.15
Modulation of non-vesicular glutamate release by pH. Nature (1996) 1.12
The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med (2013) 1.05
Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci (2013) 0.96
Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells. Biotechnol Prog (2008) 0.96
Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer (2014) 0.94
When and why amino acids? J Physiol (2009) 0.94
Glutamate transporter blockers for elucidation of the function of excitatory neurotransmission systems. Chem Rec (2008) 0.92
Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities. Curr Opin Pharmacol (2014) 0.89
Microarray analysis of 1,25(OH)₂D₃ regulated gene expression in human primary osteoblasts. J Cell Biochem (2012) 0.88
Regulation of the glutamate transporter EAAT3 by mammalian target of rapamycin mTOR. Biochem Biophys Res Commun (2012) 0.86
C6 glioma cells differentiated by retinoic acid overexpress the glutamate transporter excitatory amino acid carrier 1 (EAAC1). Neuroscience (2007) 0.84
Comparative regulation of gene expression by 1,25-dihydroxyvitamin D3 in cells derived from normal mammary tissue and breast cancer. J Steroid Biochem Mol Biol (2014) 0.83
Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One (2014) 0.83
Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS One (2014) 0.82
Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep (2015) 0.82
Gene Signatures of 1,25-Dihydroxyvitamin D3 Exposure in Normal and Transformed Mammary Cells. J Cell Biochem (2015) 0.82
Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder. Transl Psychiatry (2013) 0.81
EMT-induced metabolite signature identifies poor clinical outcome. Oncotarget (2015) 0.79
The transcriptomic response of mixed neuron-glial cell cultures to 1,25-dihydroxyvitamin d3 includes genes limiting the progression of neurodegenerative diseases. J Alzheimers Dis (2013) 0.79